Background {#Sec1}
==========

Infantile Hemangioma, a common benign tumor in childhood, occurs in 10 % of children, more frequently in prematures and females \[[@CR1]\]. It shows a cycle with three phases: an initial proliferative phase (rapid growth during the first year), a plateau and an involution phase (spontaneous regression over 1--8 years) \[[@CR2], [@CR3]\]. In a study by Chang et al. \[[@CR4]\], growth characteristics were examined in a large number (n = 526) of infantile hemangiomas and the results showed that infantile hemangioma growth occurred mainly in infancy, at a mean age of 3 months. Infantile hemangiomas may be deep or superficial, classified based on the depth of lesions. Deep infantile hemangiomas usually appear later in life and may be associated with a longer growth phase compared to the superficial form. Superficial infantile hemangiomas may be focal or segmental \[[@CR4]\]. Segmental lesions are associated with a longer proliferative phase and could require a longer period of treatment \[[@CR5]\].

The body area more frequently affected by hemangioma is the head and neck, mainly the face, with an association with the embryological development of the face \[[@CR6]\]. Available treatment for patients with infantile hemangioma includes the use of corticosteroids and/or surgical resection of the tumor. The standard of care treatment strategy is the use of propranolol hydrochloride, a β-blocker entered as a safer form of treatment for proliferating infantile hemangioma \[[@CR7], [@CR8]\]. Although the advances in therapeutic strategies for infantile hemangioma, the main clinical problems are still the lack of reliable parameters able to distinguish proliferative from involuting IH lesions and the diverse response rates of patients to treatment.

Therefore, the identification of genetic and epigenetic alterations in proliferating and involuting infantile hemangioma lesions will likely contribute to better understand the underlying molecular mechanisms of development and progression of this disease, which is a leading cause of morbidity in affected children. Indeed, differences in the expression of genomic biomarkers have been reported in infantile hemangioma; e.g., insulin-like growth factor 2 (IGF-2) was found as highly expressed in proliferative lesions compared to involuting lesions \[[@CR9]\].

In infantile hemangioma, neural crest markers (NG2 and nestin), pericytes markers (δ-like kinase, smooth muscle actin, calponin and CD90) and stem cell markers (OCT4, NANOG and SOX2) are frequently over-expressed both at mRNA and protein levels. In addition, pericytes (perivascular cells surrounding microvessels and that are related to the development and regulation of angiogenesis) and the derm of the face are derived from neural crest, suggesting that the neural crest may be involved in disease pathogenesis \[[@CR10]\]. Importantly, expression of lymphatic endothelial hyaluronan receptor-1 (LYVE-1) has been reported in kaposiform hemangioendothelioma and tufted angioma \[[@CR11]\]. LYVE-1 was detected as strongly expressed in proliferative infantile hemangiomas but not in pyogenic granulomas or intramuscular hemangioma lesions, suggesting an important role of these markers in the biology of infantile hemangioma \[[@CR12]\]. microRNAs (miRNAs) play an important role in gene expression regulation and have been demonstrated to play a role in the pathogenesis of several human diseases \[[@CR13]\]. miRNAs are small, non-coding RNAs containing \~18--24 nucleotides. They can bind to the 3' and 5'ends of the mRNA, leading, in most cases, to translation inhibition or mRNA degradation \[[@CR14], [@CR15]\]. Furthermore, miRNAs are related to important biological processes, such as embryonic development, differentiation, apoptosis, cell proliferation \[[@CR16]--[@CR18]\] and oncogenesis \[[@CR19]--[@CR21]\]. To date, 2588 miRNAs were identified and characterized as to their sequence and function in the human genome (<http://www.mirbase.org/cgi-bin/browse.pl?org=hsa>) \[[@CR22]--[@CR26]\].

Different mechanisms can lead to deregulated miRNA expression, including genomic alterations, such as DNA gains or amplifications and mutations, epigenomic changes including DNA methylation and defects in miRNA biogenesis, including transcription and processing of miRNAs \[[@CR27], [@CR28]\]. miRNAs that are altered by these mechanisms may lead to deregulated gene expression.

The understanding of genetic and epigenetic mechanisms, such as deregulated miRNA and target gene expression, as well as molecular pathways regulated by miRNAs, may contribute for the development of new strategies for diagnosis and treatment of complex human diseases \[[@CR13], [@CR14], [@CR16]\]. Currently, it is known that miRNAs and miRNA-target genes may represent useful biomarkers to help improve diagnosis, prognosis and treatment of human diseases, such as cancer \[[@CR29], [@CR30]\]. Although some gene expression studies have been previously published \[[@CR31]--[@CR37]\], there are no current data on miRNAs or deregulated protein-protein interaction networks in hemangioma. Such data integration strategy is important to understand the functional significance of deregulated genes, miRNAs and molecular pathways involved in hemangioma development and progression. In addition, miRNAs and their target genes may be clinically applicable as therapeutic targets. Indeed, a systematic integration of data derived from multiple sources may achieve the appropriate statistical power and lead to robust, reproducible and accurate predictions \[[@CR38]\].

To the best of our knowledge, there are no studies on global miRNA expression in infantile hemangioma. A recent PubMed search (August 19, 2015) showed only one published study on the involvement of miRNAs in senile hemangioma \[[@CR39]\], which reported decreased miR-424 expression and increased levels of CCNE1 and MEK1 proteins, which are targeted by miR-424, in patient samples. This study suggested that abnormal proliferation in senile hemangioma may be regulated, at least in part, by miR-424 \[[@CR39]\].

Herein, we performed a comprehensive meta-analysis of gene expression data in infantile hemangioma and identified miRNAs as potential regulators of target genes in these tumors. Gene expression datasets were integrated with miRNAs for the identification of molecular pathways potentially involved in infantile hemangioma development and progression. These data may be clinically valuable to predict which infantile hemangioma lesions may respond and which lesions will be resistant to currently available treatment modalities. Furthermore, these data are useful for the identification of robust biomarkers applicable in the development of novel and better molecularly-targeted treatment strategies in infantile hemangioma.

Methods {#Sec2}
=======

Meta-analysis of gene expression data in infantile hemangioma {#Sec3}
-------------------------------------------------------------

Meta-analysis study design followed the stages of the PRISMA Statement \[[@CR40]\] (Fig. [1](#Fig1){ref-type="fig"}). Herein, we performed a meta-analysis of previously published gene expression data in infantile hemangioma, by searching PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>). Key words used were: *"infantile hemangioma* AND *global gene expression"*, *"infantile hemangioma* AND *gene signature"*, *"infantile hemangioma* AND *microRNAs"*, *"microRNA in infantile hemangioma"*, *"infantile hemangioma* AND *microarray"*, *infantile hemangioma* AND *mRNA expression"*. Meta-analysis searches comprised studies published between the years of 2000--2015. Considering that our searches did not retrieve any records on miRNA studies in infantile hemangioma, we included only gene expression studies in this meta-analysis. Deregulated genes reported in selected studies were further used for bioinformatics prediction of miRNAs as potential regulators of gene expression, as described below.Fig. 1Flowchart of meta-analysis process

Inclusion criteria were: gene expression data in primary patient samples of infantile hemangioma or pure cell populations of infantile hemangioma, any subtype of disease, inclusion of normal tissues for comparison, data subjected to independent validation. Exclusion criteria were: non- infantile hemangioma, patients treated before molecular genetic analysis and in vivo model studies.

Identification of miRNAs as potential modulators of deregulated genes in infantile hemangioma {#Sec4}
---------------------------------------------------------------------------------------------

Deregulated genes identified in the meta-analysis were used for bioinformatics prediction of miRNAs as regulators of gene expression. We used microRNA Data Integration Portal, mirDIP \[[@CR41]\], a computational tool that integrates several predicted and validated miRNA databases. mirDIP allows searching for genes that are targeted by miRNAs as well as for miRNAs predicted to regulate genes. Additionally, relevant biological pathways for differentially expressed genes were identified using Biological Networks Gene Ontology (BiNGO) tool, application available in Cytoscape v3.1.1 \[[@CR42]\]. BiNGO allows recognizing which of Gene Ontology (GO) categories are statistically more represented in a specific set of genes. Protein-protein interaction (PPI) networks were then generated using Metasearch STRING v9.1 \[[@CR43], [@CR44]\] and visualization and annotation data of PPI and miRNA-gene interaction networks were generated using Cytoscape v3.1.1 \[[@CR45], [@CR46]\]. Furthermore, we identified drug-gene interactions using Drug-Gene Interaction Database (DGIdb), a database and web-interface for identifying known and potential drug-gene relationships. Genes were defined by Entrez Gene and Ensembl and matched with genes from drug-gene interactions and druggable gene categories. Drugs were defined by searching PubChem and then matched with drugs from drug-gene interaction data. Drug-gene interactions were obtained from multiple sources, including DrugBank, Therapeutic Target Database (TTD) and Pharmacogenomics Knowledge Base (PharmGKB) \[[@CR47]\].

Results {#Sec5}
=======

Protein-protein interaction networks Identified in infantile hemangioma {#Sec6}
-----------------------------------------------------------------------

According to the meta-analysis study design and the inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}), we selected 7 studies reporting gene expression data in infantile hemangioma \[[@CR31]--[@CR37]\] (Table [1](#Tab1){ref-type="table"}). Altogether, these studies reported a total of 54 differentially expressed genes (36 over- and 18 under-expressed) in 98 patient samples (Table [2](#Tab2){ref-type="table"}).Table 1Description of publicly available studies used in the meta-analysisReference IDSample sizeGene expression analysis and validation analysis platforms\[[@CR31]\]6 hemangiomas and 7 normal term placental tissuesU95Av2 GeneChip oligonucleotide microarrays (Affymetrix)\[[@CR32]\]7 hemangiomas (3 proliferating, 4 involuting) and 3 normal term placental tissuesHuman Genome U133 Plus 2.0 (Affymetrix)\[[@CR33]\]4 pairs of early proliferative stage and spontaneously early involution stage of the same hemangiomas, 11 hemangiomas (6 proliferative and 5 involuting), 5 controls (normal skin) Serum from 69 patients with hemangioma (46 proliferative and 23 involuting), 20 patients with venous malformations and 31 negative controls (children with cheilopalatognathus)Illumina Human-6 bead chip, QRT-PCR\[[@CR34]\] GSE43742HEMECs, HDMVECs, 16 infantile hemangioma, 4 normal controls (neonatal foreskin)Illumina HumanHT-12 V4.0 expression beadchip Immunohistochemistry\[[@CR35]\]hemSCs, bm-MPCs, HDMECs, cbEPCs and abEPCsRQ-PCR, Functional assays, Immunofluorescence\[[@CR36]\]HemSCs, HemECs, HDMECs and MSCsRQ-PCR, Immunofluorescence\[[@CR37]\]48 hemangiomas, 9 vascular malformations and vascular tumor specimens, 11 neonatal foreskin controls and HemECs from proliferating hemangiomaGeneFilter GF211 (Invitrogen)*QRT-PCR* quantitative reverse-transcription polymerase chain reaction, *HEMECs* infantile hemangioma endothelial cells, *HDMVECs* dermal microvascular endothelial cells, *HemECs* hemangioma-derived endothelial cells, *hemSCs* proliferating hemangioma-derived CD133+ cells, *HDMECs* human dermal microvascular endothelial cells, *cbEPCs* cord blood endothelial progenitor cells, *abEPCs* adult blood endothelial progenitor cells, *bm-MPCs* bone marrow-mesenchymal progenitor cells, *HemSCs* hemangioma-derived stem cells, *MSCs* mesenchymal stem cellsTable 2List of 54 deregulated genes identified in infantile hemangioma, as reported by the seven studies included in the meta-analysisGene symbolGene nameGene functionGene IDOver-expressed*SMARCE1*SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1chromatin remodelling6605*RGS5*Regulator of G-protein signaling 5cell signaling8490*CTAG2*Cancer/testis antigen 2autoimmunogenic tumor antigen30848*LTBP2*Latent transforming growth factor beta binding protein 2cell growth and differentiation4053*ANG*Angiogenin, ribonuclease, RNase A family, 5cell growth and differentiation283*IGF2*Insulin-like growth factor 2cell growth and differentiation3481*TBX2*T-box 2transcription factor6909*NOTCH3*Notch 3cell fate and signalling4854*HSD17B2*Hydroxysteroid (17-beta) dehydrogenase 2uncharacterized3294*TFPI2*Tissue factor pathway inhibitor 2tumor supressor7980*GNG11*Guanine nucleotide binding protein (G protein), gamma 11cell signaling2791*NID1*Nidogen 1cell interactions4811*COL4A1*Collagen, type IV, alpha 1basement membrane/metabolism1282*KDR*Kinase insert domain receptor (a type III receptor tyrosine kinase)cell growth and differentiation3791*FCGR2B*Fc fragment of IgG, low affinity IIb, receptor (CD32)immunocomplex phagocytosis/antibody production regulation2213*PLAGL1*Pleiomorphic adenoma gene-like 1tumor supressor5325*DLK1*Delta-like 1 homolog (Drosophila)cell growth and differentiation8788*JAM3*Junctional adhesion molecule 3cell adhesion83700*NID2*Nidogen 2 (osteonidogen)cell adhesion22795*MEOX2*Mesenchyme homeobox 2myogenesis regulation4223*GABRE*Gamma-aminobutyric acid (GABA) A receptor, epsilonsynaptic transmission2564*CEACAM1*Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)cell adhesion634*BET1*Bet1 golgi vesicular membrane trafficking proteinvesicular transport10282*MXRA5*Matrix-remodelling associated 5matrix remodelling25878*IGFBP7*Insulin-like growth factor binding protein 7cell growth and differentiation3490*NETO2*Neuropilin (NRP) and tolloid (TLL)-like 2cell signaling81831*BAI3*Brain-specific angiogenesis inhibitor 3angiogenesis577*PLXDC1*Plexin domain containing 1uncharacterized57125*JAG1*Jagged 1hematopoiesis182*EDNRA*Endothelin receptor type Acell signaling1909*ICAM2*Intercellular adhesion molecule 2cell adhesion3384*NOTCH4*Notch 4cell fate4855*STAB1*Stabilin 1cell growth and differentiation23166*EPHB3*EPH receptor B3cell signaling2049*LPHN1*Latrophilin 1cell adhesion/signal transduction22859*NPR1*Natriuretic peptide receptor 1cell signaling4881Under-expressed*GPR37*G protein-coupled receptor 37 (endothelin receptor type B-like)cell signaling2861*IGFBP3*Insulin-like growth factor binding protein 3cell growth and differentiation3486*FLT1*Fms-related tyrosine kinase 1cell growth and differentiation2321*PDGFRA*Platelet-derived growth factor receptor, alpha polypeptidecell growth and differentiation5156*TGFBR3*Transforming growth factor, beta receptor IIIcell growth and differentiation7049*LPAR1*Lysophosphatidic acid receptor 1cell growth and differentiation1902*IGFBP5*Insulin-like growth factor binding protein 5cell growth and differentiation3488*EDNRB*Endothelin receptor type Bcell signaling1910*PDGFC*Platelet derived growth factor Ccell growth and differentiation56034*BMP4*Bone morphogenetic protein 4cell growth and differentiation652*ANGPTL1*Angiopoietin-like 1cell growth and differentiation9068*VCAM1*Vascular cell adhesion molecule 1cell adhesion7412*BMP5*bone morphogenetic protein 5cell growth and differentiation653*IGF1R*Insulin-like growth factor 1 receptorcell growth and differentiation3480*ANGPT2*Angiopoietin 2vascular remodeling285*ANTXR1*Anthrax toxin receptor 1cell signaling84168*CLDN11*Claudin 11cell adhesion5010*KISS1*KiSS-1 metastasis-suppressorcell adhesion3814

Enrichment pathways analysis showed information on the biological role of differentially expressed genes in infantile hemangioma. Gene Ontology (GO) categories were divided into 3 hierarchically structured groups, in order to identify proteins encoded by deregulated genes in infantile hemangioma, and associated with biological processes, molecular functions and cellular components. The top 10 statistically significant enriched GO terms are shown in Fig. [2](#Fig2){ref-type="fig"}. Integrated, complex interactome analysis for deregulated genes in infantile hemangioma and functional annotations are shown in Fig. [3](#Fig3){ref-type="fig"}. A higher number of interactions was identified between genes with roles in vascular and matrix remodeling, hematopoiesis, cell growth and differentiation and transcriptional control. An interaction network between genes and miRNAs predicted to regulate the expression of these specific genes is shown in Fig. [4](#Fig4){ref-type="fig"}. The red and green triangles represent up-regulated and down-regulated genes, respectively. Notably, DGIdb data showed that 5 genes were predicted to interact with drugs that have been demonstrated as clinically useful in other tumor types (Table [3](#Tab3){ref-type="table"}).Fig. 2The top 10 enriched Gene Ontology terms of differentially expressed genes. **a**. molecular function (P value ≤ 1,87E-02); **b**. biological process (P value ≤ 3,98E-08); **c**. cellular component (P value ≤ 7,98E-02)Fig. 3Protein-protein interaction network. The blue lines highlight the interactions of VEGFA, TBX2, JAG1, ANGPT2 and MXRA5. STRING v9.1 was used to generate protein interactions and the result of the network was visualized using Cytoscape v3.1.1Fig. 4miRNA-gene interaction network. The larger the triangle edge, the higher is the number of interactions identified. The gray circles are miRNAs and blue lines highlights the interactions. The grid only groups miRNAs and genes with few interactions. The miRNA-gene interactions were visualized using Cytoscape v3.1.1Table 3Potential target agents identified based on protein-protein interaction networks of deregulated genes in infantile hemangiomaGene symbolGene nameSelected target agentClinical relevance*EDNRA*endothelin receptor type AZibotentan, AtrasentanColorectal \[[@CR62]\], prostate \[[@CR63]\] and renal cell \[[@CR64]\] carcinomas*IGF1R*insulin-like growth factor 1 receptorLinsitinib, Ganitumab, Figitumumab, Dalotuzumab, Cixutumumab, RobatumumabAdrenocortical \[[@CR65]\], ovarian \[[@CR66]\], non-small cell lung \[[@CR67]\], colorectal \[[@CR68], [@CR69]\] carcinomas and soft tissue sarcoma \[[@CR70]\]*PDGFC*platelet derived growth factor CSunitinibRenal cell carcinoma \[[@CR71]\] and breast carcinomas \[[@CR72]\]*PDGFRA*platelet-derived growth factor receptor, alpha polypeptideMotesanib, Ramucirumab, Midostaurin, Amuvatinib, Nintedanib, Pazopanib, Tandutinib, Crenolanib, Nilotinib, Masitinib, Sorafenib, Sunitinib, Regorafenib, Dovitinib, Telatinib, Vatalanib, Axitinib, Lenvatinib, ImatinibColorectal \[[@CR73], [@CR74]\], hepatocellular \[[@CR75]--[@CR78]\], kidney \[[@CR79]\], non-small \[[@CR80]\] and small cell lung \[[@CR81]\], pancreatic \[[@CR82]--[@CR84]\], colon \[[@CR85]\], gastrointestinal \[[@CR86]\], renal cell \[[@CR71], [@CR87]\], breast \[[@CR72], [@CR88]\], melanoma \[[@CR89]\], thyroid \[[@CR90]\] carcinomas and soft tissue sarcoma \[[@CR91]\]*VEGFA*vascular endothelial growth factor AZiv-aflibercept, Bevacizumab, Sorafenib tosylate, Lenalidomide, Thalidomide, AfliberceptColorectal \[[@CR92], [@CR93]\] ovarian \[[@CR94]\], non-small cell lung \[[@CR95]\], hepatocellular \[[@CR96]\] carcinomas and multiple myeloma \[[@CR97]\]

Discussion {#Sec7}
==========

Molecular pathways deregulated in hemangioma {#Sec8}
--------------------------------------------

Molecular pathogenesis of infantile hemangioma is not well understood. Advances in methods of global genetic and epigenetic analyses represent an extremely valuable approach for the identification of disease development mechanisms and have the potential to identify biomarkers and/or pathways that may be useful for the development of better treatment approaches, including molecularly-targeted therapies.

Our meta-analysis approach allowed us to integrate mRNA expression data in infantile hemangioma and to predict which miRNAs are potential regulators of gene expression. Among the different mechanisms that can lead to gene expression alterations; miRNA alteration is an important mechanism of over- or under-expression of target genes \[[@CR48]\]. Herein, we aimed to utilize data on deregulated genes in infantile hemangioma, in order to predict which miRNAs could potentially regulate these genes, and to construct interaction networks between genes and miRNAs.

Gene enrichment analysis showed that deregulated genes previously reported in infantile hemangioma \[[@CR31]--[@CR37]\] are mainly involved in cell signaling and angiogenesis, functioning in vascular and matrix remodeling, hematopoiesis, cell growth and differentiation and transcriptional control.

It is known that the formation of vascular tumors including infantile hemangioma is partly related to increased expression of angiogenic growth factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), which lead to the development of a disorganized blood vessel mass \[[@CR49]\]. Indeed, angiogenesis is mainly regulated by the vascular endothelium \[[@CR50]\].

miRNAs control and modulate cell response of vascular endothelium to angiogenic stimuli; for example, miR-126 is a positive regulator of angiogenic signaling and vascular endothelial integrity. Vascular development defects were demonstrated in an in vitro model of miR-126-depleted cells, which did not respond to bFGF and VEGF angiogenic factors \[[@CR51]\]. Angiogenic response is also controlled by miRNAs, such as miR-221 and miR-222, which play a role as inhibitors of stem cell factors. Other miRNAs, such as miR-27b and miR-let-7f, play a pro-angiogenic role, since their expression promotes angiogenesis \[[@CR51]\]. Notably, miRNA expression in vascular endothelial cells can be modified in response to cellular stimuli or to the microenvironment. For example, a hypoxic environment promotes the production of miR-210, which has pro-angiogenic activity. Therefore, increase in pro-angiogenic miRNA expression in endothelial cells may stimulate the production of angiogenic factors, contributing to the process of tumorigenesis \[[@CR51]\].

VEGFA plays an important role in vascular development and in pathological angiogenesis and its protein is highly expressed in vessels of proliferating infantile hemangioma \[[@CR52]\]. Interestingly, angiogenin protein (ANG), which is required for cell proliferation and is an important mediator of blood vessel formation, regulates VEGFA expression \[[@CR53]\]. Although VEGFA was not identified among the deregulated genes reported in the studies used for meta-analysis, VEGFA is shown in the PPI and miRNA-gene interaction networks, likely due to its important role in angiogenesis and to its indirect interaction with other proteins in the network.

To our knowledge, the only available previously published study on miRNAs in hemangioma identified miR-424 under-expression in senile hemangioma \[[@CR39]\]. miR-424 is shown interacting with VEGFA in our miRNA-gene network analysis. miR-424 over-expression has been associated with greater cell motility, decreased cell adhesion and other alterations associated with epithelial-to-mesenchymal transition (EMT) \[[@CR54]\]. Notably, this study showed that miR-424 expression levels are increased in primary tumors and decreased in metastasis compared to primary breast tumors and additional functional data suggested that miR-424 may play different roles in the different stages of tumor development and progression \[[@CR54]\].

Several genes with roles in vascular and matrix remodeling, hematopoiesis, cell growth and differentiation and transcriptional regulation were shown in the PPI and miRNA-gene interation network. Among these, ANGPT2, MXRA5, JAG1, VEGFA and TBX2 showed a large number of interactions. Interestingly, some of these genes also play roles in cell signaling pathways that have been linked to the pathogenesis of infantile hemangioma \[[@CR55]\]; namely, VEGFA in the VEGF/VEGFR pathway, ANGPT2 and ANGPTL1 in the Tie2/Angiopoietin signaling pathway and NOTCH3, NOTCH4 and JAG1 in the Notch pathway. Growth factors and angiopoietins have roles in embryonic development and angiogenesis-dependent diseases and Notch components are involved in modulation of cell fate and differentiation \[[@CR55]\].

Herein, miRNA-gene interaction networks generated by integrative meta-analysis showed miRNAs with a large number of interactions (miR-9, miR-939, and let-7 family of miRNAs); these miRNAs are likely acting as main regulators in the network. Notably, miR-9 has been demonstrated as pro-metastatic and suppressor of E-cadherin in breast cancer cells, promoting cell motility and increasing invasive potential of carcinoma cells, besides activating β-catenin signaling, which in turn contributes to high VEGFA expression and consequently to induction of angiogenesis \[[@CR56]\]. Increased miR-9 expression levels were also associated with EMT in breast cancer cells and with poor prognosis of patients with breast cancer \[[@CR57]\]. In ovarian cancer, miR-939 plays an important role in the progression and regulation of cell growth and cell cycle; it has been demonstrated that ES-2 cells transfected with miR-939 mimic show APC2 decreased expression, suggesting that APC2 may be a target of miR-939 \[[@CR58]\].

A recent meta-analysis suggested that the let-7 family of miRNAs are potential biomarkers for tumor grade prediction in breast cancer \[[@CR59]\] as well as in other cancers, since let-7 family is highly conserved across species \[[@CR60]\].

Among other miRNAs with a significant number of interactions, miR-637 links to main networks through direct interactions with VEGFA and CEACAM; the latter interacting with miR-9 and miR-939. Functional data has shown that miR-637 is one of the effective regulators of HER2 signaling; in HER2-positive trastuzumab non-responsive cell lines, miR-637 was efficient to inhibit breast cancer cell growth \[[@CR61]\].

Conclusion {#Sec9}
==========

Herein, we identified several interconnected genes and miRNAs as potential regulators of gene expression. Such miRNAs and genes may play important roles in the development and progression of infantile hemangioma. Additionally, these molecules show potential to be targets for drugs that may be clinically useful in the development of new therapies for infants and children affected by this tumor. Data generated herein may be used for validation of expression of miRNAs and genes regulated by miRNAs in infantile hemangioma. Validation analysis in a large representative cohort of primary untreated patient samples is necessary in order to establish robust biomarkers for prediction of treatment response and for the development of better treatment modalities.
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